Literature DB >> 4358998

Physostigmine in choreiform movement disorders.

D Tarsy, N Leopold, D S Sax.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4358998     DOI: 10.1212/wnl.24.1.28

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

Review 1.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

2.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

4.  Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.

Authors:  A J Stoessl; C T Dourish; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Pharmacological options for the management of dyskinesias.

Authors:  H Shale; C Tanner
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

6.  2-dimethylaminoethanol (Deanol) in Huntington's chorea.

Authors:  T A Caraceni; F Girotti; I Celano; E Parati; L Balboni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-12       Impact factor: 10.154

7.  Effects of cholinergic and anticholinergic drugs on ketamine-induced linguopharyngeal motor activity.

Authors:  L A Marco; R S Joshi; C Brown; L D Aldes; R B Chronister
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Pharmacological characterization of tardive dyskinesia.

Authors:  D E Casey; D Denney
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

9.  Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.

Authors:  K L Davis; K F Faull; L E Hollister; J D Barchas; P A Berger
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.